top
Search terms
Results 1 - 7 of 7 - ordered by :
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, Review, Anne E. de Leeuw, Rudolf A. de Boer

Date : 01/10/2016 Item size : 586778 bytes
Ehjcvp

Mean blood glucose changes in the placebo group were 0.6mmol/L (±3.1, P0.0002), 0.2 mmol/L (±2.7, P0.04), and 0.1 mmol/L (±3.0, P0.01) in the moderate, modest, and mild weight loss groups, ...

European Heart Journal - Cardiovascular Pharmacotherapy, Original Article, Sadaf Kamil, Nicholas Finer, William Philip T James, Ian D. Caterson, Charlotte Andersson, Christian Torp-Pedersen

Date : 27/09/2016
Ehjcvp

Given the burden of cardiovascular disease in patients with diabetes, the focus should shift towards cardiovascular outcome studies designed to evaluate efficacy (i.e. to determine the efficacy of a ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Faiez Zannad, Wendy Gattis Stough, Raymond J. Lipicky, Juan Tamargo, George L. Bakris, Jeffrey S. Borer, Maria de los Angeles Alonso ...

Date : 01/07/2016 Item size : 285307 bytes
Ehjcvp

[...]SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but also to target other cardiovascular risk factors. SGLT2 ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Anne E. de Leeuw, Rudolf A. de Boer

Date : 18/04/2016 Item size : 590679 bytes
Ehjcvp

ApoA-I Milano (apoA-IM) is a natural variant of human apoA-I identified in individuals in northern Italy, which results from the replacement of arginine by cysteine at position 173 of the apoA-I ...

European Heart Journal - Cardiovascular Pharmacotherapy, INVITED EDITORIAL, Antonio J. Vallejo-Vaz, Kausik K. Ray

Date : 01/01/2016 Item size : 167390 bytes
Ehjcvp

Effects of reninangiotensinaldosterone system blockade on cardiovascular system The benefits of blocking the RAAS in heart failure (HF) and post-myocardial infarction (MI) were largely proved many ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Gema Ruiz-Hurtado, Luis Miguel Ruilope

Date : 01/04/2015
Ehjcvp

Proposed underlying mechanisms and heterogeneity in study endpoint definitions Various mechanisms have been described that may be responsible for the clinical presentation of angina pectoris in the ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Peter Ong, Anastasios Athanasiadis, Udo Sechtem

Date : 01/01/2015